iECURE

Philadelphia, United States Founded: 2020 • Age: 6 yrs
Online genetic engineering tools for drug development are provided.

About iECURE

iECURE is a Healthcare company based in Philadelphia (United States) founded in 2020. Online genetic engineering tools for drug development are provided. iECURE has raised $115 million across 2 funding rounds from investors including Orbimed, Novo Holdings and LYFE Capital. The company has 7 employees. Its chief executive, as recorded, is Joseph Truitt. iECURE offers products and services including ECUR-506. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Discovery. Its legal entity is iECURE, Inc. Its competitors include BridgeBio, Spark Therapeutics and Alnylam; 3 of its 3 listed competitors have raised funding.

Company details

iECURE was founded in 2020 in Philadelphia, United States. Operations center on biotechnology, with an online platform used for genetic engineering in drug development. In vivo gene insertion therapies are developed to address rare pediatric liver diseases, including ARCUS-mediated candidates. Focus remains on therapeutic advancements for these conditions, supported by expertise in gene therapy applications.

  • Headquarters Philadelphia, United States
  • Employees 7
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website iecure.com
  • Social LinkedIn
  • Legal Name Iecure, Inc.
Key Metrics
  • Total Equity Funding
    $115M (USD)

    in 2 rounds

  • Latest Funding Round
    $65M (USD), Series A

    Nov 2022

  • Investors
    Orbimed

    & 3 more

  • Employee Count
    7

Products & Services of iECURE

iECURE offers a comprehensive portfolio of products and services, including ECUR-506.

ECUR-506
Gene Editing Therapy

In vivo treatment for ornithine transcarbamylase deficiency via gene insertion

Funding Insights of iECURE

iECURE has successfully raised a total of $115M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $65 million completed in November 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $115M
  • Total Rounds 2
  • Last Round Series A β€” $65M
  • First Round $50M

    (Sep 2021)

  • Investors Count 4

All 2 funding rounds of iECURE with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Nov 2022$65MSeries A–Novo Holdings, LYFE Capital
Sep 2021$50MSeries A–Versant Ventures, Orbimed
–
Valuation history

4 investors in total: 4 institutional.

Investors in iECURE

iECURE has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include Orbimed, Novo Holdings and LYFE Capital.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
Private equity and venture capital fund focused on the healthcare sector
novoholdings.dkHellerup, Denmark
LYFE Capital is recognized as a premier healthcare investment platform.
lyfecapital.comMenlo Park, USA
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999.
versantventures.com
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
1989orbimed.comNew York, United States
Premium access

Investor details for iECURE

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of iECURE

25 people are tracked at iECURE (15 in leadership, 7 in board & advisors, 3 in team); the tracked headcount is 7.

NameRoleGroup
Joseph Truitt
CEOLeadership
Patricia Ward
Senior Director, Quality & ComplianceLeadership
Paul Firuta
COOLeadership
Kimberly M. Smith
VP, Finance & AccountingLeadership
Alex Monteith
Chief Business OfficerLeadership
David Garrett
CFOLeadership
Gabriel M. Cohn
Chief Medical OfficerLeadership
George Diaz
VP, Therapeutic Area Lead, Urea Cycle DisordersLeadership
Matthew Hall
VP, Head of Clinical OperationsLeadership
Mark J. Semanick
VP, Head of Technical OperationsLeadership
Maryann A. Toto
VP, Head of Regulatory AffairsLeadership
Dave Lecher
Senior Director Of Supply ChainLeadership
Mike Burnham
Senior Director Manufacturing Sciences & Technology LeadLeadership
Karen Kuhn
Sr. Director Clinical OperationsLeadership
John Blackwell
VP Quality And ComplianceLeadership
Brian Di Donato
DirectorBoard & advisors
Ray Camahort
DirectorBoard & advisors
Tal Zaks
DirectorBoard & advisors
James M. Wilson
Chief Scientific AdvisorBoard & advisors
Tom Woiwode
ChairBoard & advisors

5 more people are available in the full profile.

Premium access

Complete people profiles for iECURE

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of iECURE

3 dated milestones of iECURE across 2 years, from founding to its latest funding, stage changes and deals.

  1. Founded iECURE is founded.
  2. Funding First funding round of $50.0M.
  3. Funding Latest funding round, Series A, of $65.0M.

Competitors of iECURE

iECURE has 3 listed competitors in our database, 3 of them funded. They include BridgeBio, Spark Therapeutics and Alnylam.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
bridgebio.com2015Palo Alto, United States$434.2M
Therapeutics for genetic diseases are developed through targeted interventions.
sparktx.com2013Philadelphia, United States$82.8M822
Gene therapies for rare diseases including retinal dystrophies are developed.
alnylam.com2002Cambridge, United States$17M2,100
RNA interference-based therapeutics are developed for multiple disorders.
Premium access

Detailed competitors of iECURE

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of iECURE

The website of iECURE (iecure.com) receives about 3.7K visits a month.

  • Monthly visits
    3.7K

    ▲ 26% vs previous month

Top companies in Genomics & Gene Therapy Platforms

3 companies that operate in the same segment as iECURE (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Digital sequencing technology for cancer detection is developed.
2012Redwood City, California, United StatesUSD 557.5 MUSD 982.02 M4,867
Circulating tumor DNA is screened for early cancer detection.
2016Menlo Park, California, United StatesUSD 2 BUSD 147.17 M1,141
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Iecure

Premium access

Complete news archive for iECURE

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about iECURE

iECURE was founded in 2020 and raised its 1st funding round 1 year after it was founded.

iECURE is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania, United States.

Joseph Truitt is the CEO of iECURE, as recorded in our data.

iECURE is a funded company, having raised a total of $115M across 2 funding rounds to date. The company's 1st funding round was a Series A of $50M, raised on Sep 2021.

iECURE has 7 employees.

iECURE was founded in 2020 in Philadelphia, United States. Operations center on biotechnology, with an online platform used for genetic engineering in drug development. In vivo gene insertion therapies are developed to address rare pediatric liver diseases, including ARCUS-mediated candidates. Focus remains on therapeutic advancements for these conditions, supported by expertise in gene therapy applications.

iECURE's top competitors include Spark Therapeutics, BridgeBio and Alnylam.

iECURE offers ECUR-506.

iECURE has 4 investors. Key investors include Orbimed, Novo Holdings, LYFE Capital, and Versant Ventures.

iECURE operates through Iecure, Inc..

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available